Phase III randomized controlled trial to confirm efficacy of surgery plus postoperative dose-modified S-1 adjuvant chemotherapy against surgery alone for vulnerable elderly patients with pathological stage II/III gastric cancer: JCOG1507 (BIRDIE trial).

Journal of Clinical Oncology 2026

View at publisher
Authors: Itaru Yasufuku, Kazuhiro Yoshida, Kazuya Yamaguchi, Masayuki Yokoyama, Masahide KAJI, Sang-Woong Lee, Yasuhiro Choda, Shinichi Sakuramoto, Naoki Okumura, Hiroshi Katayama, Haruhiko Fukuda, Yukinori Kurokawa
+2 more Narikazu Boku, Takaki Yoshikawa
DOI: 10.1200/jco.2026.44.2_suppl.347
Cited by: 0

Abstract

347 Background: In Japan, the standard treatment for resectable gastric cancer is primary gastrectomy followed by adjuvant chemotherapy based on S-1. However, the survival benefit of adjuvant chemotherapy in elderly patients, particularly those considered vulnerable, remains uncertain. Methods: JCOG1507 (BIRDIE trial) was a phase III randomized controlled trial to confirm the superiority of dose-modified S-1 adjuvant chemotherapy to surgery alone for vulnerable elderly patients with pathological stage II/III gastric cancer. The trial was conducted at 45 institutions of the Stomach Cancer Study Group of the Japan Clinical Oncology Group. Vulnerability to S-1 was defined as: (1) weight loss

Fields of Study & Subjects

Gastric Cancer Management and Outcomes Pancreatic and Hepatic Oncology Research Intraperitoneal and Appendiceal Malignancies

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
347–347
Publication date
10 January 2026
Language
EN